Table 3. Association between EPHA1 expression and clinicopathological factors in patients with gastric cancer.
| Characteristic | Number of studies | Number of patients | Pooled OR (95% CI) | P value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I2 (%) | P value | Model | |||||
| Age (old vs. young) | 3 | 481 | 1.02 (0.69–1.52) | 0.917 | 0.0 | 0.804 | Fixed |
| Sex of patients (male vs. female) | 3 | 481 | 1.15 (0.74–1.78) | 0.539 | 0.0 | 0.441 | Fixed |
| Tumor grade (high vs. low) | 3 | 481 | 1.83 (0.80–4.17) | 0.153 | 76.6 | 0.014 | Random |
| Tumor stage (high vs. low) | 3 | 481 | 1.74 (1.15–2.61) | 0.008 | 35.5 | 0.212 | Fixed |
| Lymph node metastasis (present vs. absent) | 3 | 481 | 1.88 (1.24–2.87) | 0.003 | 26.8 | 0.255 | Fixed |
| TNM stage (high vs. low) | 2 | 367 | 4.98 (1.00–24.91) | 0.051 | 82.2 | 0.018 | Random |
EPHA1, ephrin receptor A1; OR, odds ratio; CI, confidence interval; TNM, tumor-node-metastasis.